( MENAFN - GlobeNewsWire - Nasdaq) New York, New York, Oct. 23, 2024 (GLOBE NEWSWIRE) -- DT Cloud Acquisition Corporation (Nasdaq: DYCQU, DYCQ, DYCQR) (“DT Cloud” or the“SPAC”), a publicly-traded special purpose acquisition company, and Maius Pharmaceutical Co., Ltd.
(“Maius” or the“Company”), a biopharmaceutical R&D company, announced that they had entered into a definitive business combination agreement (the“Business Combination Agreement”) for the merger transactions (the“Business Combination,” and the transactions in connection with the Business Combination collectively, the“Transaction”). As contemplated in the Business Combination Agreement, upon closing of the Transaction, Maius will become a wholly-owned subsidiary of Maius Pharmaceutical Group Co., Ltd.
, a newly formed holding company (“Pubco”), the securities of which will be listed on The Nasdaq Stock Market LLC (“Nasdaq”). Maius is a biopharmaceutical R&D company focusing on innovative formulations and targeted small-molecule chemical drugs. The Company focuses on developing new drugs in three major areas: anticancer drugs, autoimmune medication and anti-infectives.
Its core products include small-molecule chemical drug candidates and peptide drug candidates. It has independently established an integrated drug development platform, combining a chemical drug screening system with a drug delivery system. Transaction Overview Upon consummation of the Business Combination, the outst.
